We are raising, and we would like to hear from you
T-Hawk is seeking $500K to $1M in seed capital to convert a validated scientific thesis into filed intellectual property and characterized development candidates.
Seed round, $500K to $1M
Sized to carry the portfolio from discovery through lead identification on the disclosed programs, with provisional patents filed and third-party electrophysiology data in hand. T-Hawk is virtual-first: the money buys assets and IP, not a building.
C-corporation conversion planned
T-Hawk currently operates as Jung Life Sciences LLC, an Arizona limited liability company. The company plans to convert to a C-corporation ahead of closing an equity investment. That is the structure institutional and angel investors expect, and the structure that starts the qualified small business stock clock for founders and early investors. Conversion mechanics and timing are being finalized with counsel.
Characterization
Genomics and Proteomics at institutional analytics partners.
Validation
Ion channel patch clamp validation at specialist CROs, plus reference peptide procurement.
Intellectual property
Provisional and follow-on patent filings covering initial target activities.
Team
Scientific and financial advisory board build-out across four open seats.
An NIH SBIR Phase I application is targeted for September 5, 2026, framed around the convergence thesis and the opioid-alternative opportunity. T-Hawk is also engaged with Arizona's bioscience ecosystem (AZ Bio membership, Arizona Bioscience Week, and the White Hat Investor Conference in October 2026), and expects to pursue Arizona R&D and angel investment tax credit certification, which materially improves the after-tax position of qualifying Arizona investors.
| Status | Activity / goal | Timing |
|---|---|---|
| Completed | Establish Jung Life Sciences LLC | May 2026 |
| Completed | Secure thawklifesciences.com domain | April 2026 |
| Completed | Join AZ Bio as a Core Startup member | May 2026 |
| Completed | File trademark application, “T-Hawk Life Sciences” | June 2026 |
| Completed | BIO 2026: company introduction, networking, partner identification | June 22–25, 2026 |
| In progress | Expand thawklifesciences.com as a fundraising and recruiting tool | June–July 2026 |
| In progress | File provisional patent(s) covering initial target activities | July–October 2026 |
| In progress | Establish proteomics / genomics relationships | June–August 2026 |
| In progress | Seek $500K to $1M seed funding | June–October 2026 |
| Planned | Collect organisms and venom | June–September 2026 |
| Planned | Characterize samples using proteomics and genomics | July–October 2026 |
| Planned | Select scientific and financial advisory board members | July–September 2026 |
| Planned | File NIH SBIR grant application | September 5, 2026 |
| Planned | Arizona Bioscience Week and White Hat Investor Conference | October 2026 |
Investor inquiries
- Contact
- Thomas Jung, M.S., Founder and CEO
- tom@thawklifesciences.com
- Web
- thawklifesciences.com
- Entity
- Jung Life Sciences LLC d/b/a T-Hawk Life Sciences℠ · Tucson, Arizona
- Diligence
- Compound-, organism-, and sequence-level data available to qualified parties under executed NDA.
This page is provided for informational purposes only. It is not an offer to sell, or a solicitation of an offer to buy, any security, and it is not investment, legal, or tax advice. Any offering would be made only to qualified investors through definitive transaction documents. Forward-looking statements regarding development plans, timing, corporate structure, tax treatment, and funding involve risks and uncertainties, and actual results may differ. Preclinical programs described here have not been evaluated by the FDA and are not approved for any use.